跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 11 条关于
“ImmuneOnco”
全部
11
临床试验
0
药物
0
机构
2
资讯
9
去年
ImmuneOnco's IMM27M Shows Promise in Phase I Breast Cancer Trial, Advancing to Phase II
去年
Instil Bio's Partner ImmuneOnco Doses First Patient in NSCLC Trial with IMM2510/SYN-2510
去年
Instil Bio and ImmuneOnco Advance PD-(L)1xVEGF Bispecific Antibody Clinical Development Strategy
去年
ImmuneOnco's CD47xCD20 Bispecific IMM0306 Advances to Phase II with Promising Efficacy in B-Cell Lymphomas
8个月前
Instil Bio Terminates Licensing Agreement and Discontinues Lead Cancer Drug Development
去年
Jefferies Upgrades Instil Bio, Highlighting Potential of SYN2510 in Cancer Treatment
2年前
CD47-Targeted Immunotherapies Show Promise in Cancer Treatment
去年
Immuneoncia Therapeutics Raises $24M in Successful Kosdaq IPO for Cancer Drug Development
去年
ImmuneOncia Partners with WuXi Biologics to Advance Anti-PD-L1/CD47 Bispecific Antibody IOH-001